Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 63
- Registration Number
- NCT05312671
- Locations
- 🇺🇸
Johns Hopkins University: Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 122
- Registration Number
- NCT05300282
- Locations
- 🇮🇹
Ematologia - ASST Spedali Civili di Brescia, Brescia, Italy
🇮🇹Ematologia - Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy
🇮🇹SC Ematologia - ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT05295212
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
- Conditions
- Recurrent Rhabdoid TumorRefractory Epithelioid SarcomaRefractory Kidney Medullary CarcinomaRefractory Malignant Solid NeoplasmEpithelioid SarcomaMalignant Solid NeoplasmKidney Medullary CarcinomaRecurrent Epithelioid SarcomaRecurrent Malignant Solid NeoplasmRefractory Atypical Teratoid/Rhabdoid Tumor
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT05286801
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT05251948
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University, Hangzhou City, China
🇨🇳Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou City, China
🇨🇳The General Hospital of People?s Liberation Army (301 Hospital), Beijing City, China
Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
- Conditions
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Treos Bio Limited
- Target Recruit Count
- 18
- Registration Number
- NCT05243862
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Interventions
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Galecto Biotech AB
- Target Recruit Count
- 88
- Registration Number
- NCT05240131
- Locations
- 🇫🇷
CHRU, Tours, France
🇵🇱Samodzielny Publiczny Zespol Gruzlicy I Chorob Pluc, Olsztyn, Poland
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)
- Conditions
- Interventions
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 460
- Registration Number
- NCT05224141
- Locations
- 🇯🇵
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba, Japan
🇨🇦Lakeridge Health ( Site 0102), Oshawa, Ontario, Canada
🇩🇪LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein, Germany
A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-27
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT05211323
- Locations
- 🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 3
- Registration Number
- NCT05191797
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.